Stock Taper
SCREENER COMPARE ANY 2 STOCKS
ZYME
ZYMEWORKS INC.
NASDAQ
$28.27
▼ DOWN 2.55% (-0.74)

KEY STATISTICS

Market Cap$2.08 B
52w High$30.62
52w Low$13.60
Dividend Yield—
Frequency—
P/E-14.00
Volume542.06K
Shares Out.73.57M

COMPANY

LEADERSHIP

Kenneth H. Galbraith
CHIEF EXECUTIVE
Kenneth H. Galbraith

COMPENSATION 2026

Salary$654,833
Stock Awards$2,112,000
Incentive Plan Pay$361,652
All Other Comp.$139,459
Total$5,253,616

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 28, 2017
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
231

PRICE TARGET

Target High$55.00
Target Low$32.00
Target Median$43.00
Target Consensus$42.17

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$231.79M
NOV
5
THU

PRICE

$28.27 ▼ DOWN 2.55% (−$0.74)
$28.25$28.50$28.759:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM28.27

About Zymeworks Inc.

https://www.zymeworks.com ↗

Zymeworks Inc. is a Vancouver-based clinical-stage biopharma developing cancer biotherapeutics like zanidatamab and ZW49, with partnerships including Merck, Lilly, and Bristol-Myers.

INDUSTRY

Biotechnology

A PRODUCT ZYMEWORKS INC. IS KNOWN FOR

Ziihera® (zanidatamab-hrii)
Ziihera® (zanidatamab-hrii)

Ziihera® is a Zymeworks-developed bispecific HER2 antibody, FDA-approved for HER2-positive biliary tract cancer, marking their first approved therapy, commercialized via partnerships with Jazz Pharmaceuticals and BeiGene.

COMPETITORS

COMPETITOR
AZN COMPARE
GMAB COMPARE
MGNX COMPARE
REGN COMPARE

Revenue by Products

IconPRODUCTQ3-2025Q4-2025Q1-2026Q2-2026
Milestone Revenue$25M — — —
Upfront Fee— $18M — —
Royalty$831K — $1.33M ▲$1.59M ▲
Research Support Payments And Other Service$352K — $392K ▲$291K ▼

ETFS HOLDING THIS STOCK

ETFS HOLDING
129
LISTED HERE
23
RANKED BY POSITION SIZE
VTS.AX
0.00% · 1.5M
IWM
0.04% · 1.2M
D5BM.DE
0.10% · 336.8K
DFAS
0.03% · 189.4K
CANC
1.48% · 110.6K
ZPRR.DE
0.05% · 94.5K
FESM
0.04% · 90.1K
FYC
0.14% · 71.3K
PRFZ
0.07% · 67.8K
BBP
1.56% · 64.0K
FSML
1.13% · 58.8K
CN
CNCR
3.45% · 41.6K
RSSL
0.04% · 22.4K
FSCC
0.15% · 19.0K
GSSC
0.05% · 18.9K
SGRW
0.76% · 7.8K
ETLZ.DE
0.08% · 6.1K
TILT
0.01% · 5.5K
RFLR
0.11% · 3.8K
BIB
0.07% · 2.6K
USUE.DE
0.00% · 185
RESM
0.07% · 139
RGSC.L
0.22% · 0

INSTITUTIONAL OWNERSHIP

SHARES OWNED
84.91%
HOLDERS
292
TOP 12 OF 292 · RANKED BY POSITION SIZE
Ecor1 Capital, LLC
23.0M sh · $575.18M
Rubric Capital Management LP
7.0M sh · $175.28M
Blackrock, Inc.
4.6M sh · $121M
Blackrock Inc.
4.2M sh · $35.69M
Perceptive Advisors LLC
4.2M sh · $109.34M
Morgan Stanley
4.0M sh · $68.06M
Bvf Inc/Il
3.9M sh · $67.27M
Redmile Group, LLC
3.7M sh · $63.29M
Vanguard Group Inc
2.3M sh · $61.32M
Bnp Paribas Asset Management Holding S.A.
1.9M sh · $47.78M
Credit Suisse AG/
1.9M sh · $19.94M
Vestal Point Capital, LP
1.8M sh · $30.15M

RATINGS SNAPSHOT

Overall rating: D+

DCFROEROAD/EP/EP/B
Discounted Cash Flow1
Return On Equity1
Return On Assets1
Debt To Equity1
Price To Earnings1
Price To Book1
Overall Score1

INSIDER TRADES

★
OFFICER: EVP & CHIEF OPERATING OFFICER
Hollywood Mark
Purchase · 939 shares
2026-07-06
★
OFFICER: EVP, GENERAL COUNSEL
Schneider Paul R
Purchase · 178.0K shares
2026-05-13
★
OFFICER: EVP, GENERAL COUNSEL
Schneider Paul R
Purchase · 119.0K shares
2026-05-13
★
OFFICER: EVP, GENERAL COUNSEL
Schneider Paul R
— · —
2026-05-13

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 4
OVERWEIGHT 2
OUTPERFORM 2
8 GRADES IN THE LAST 12 MONTHS
B. Riley Securities BUY Wells Fargo OVERWEIGHT Truist Securities BUY HC Wainwright & Co. BUY Evercore ISI Group OUTPERFORM Leerink Partners OUTPERFORM Stifel BUY JP Morgan OVERWEIGHT

SECTORS PEERS

PEERPRICE
SYRE$90.36COMPARE
IMNM$27.57COMPARE
BCRX$9.82COMPARE
PHVS$35.32COMPARE
TRVI$16.79COMPARE
NTLA$12.87COMPARE
MAZE$27.44COMPARE
WVE$5.04COMPARE